Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
Lieke H RoestLeanne J KosseJette A van LintHelen R GosseltJoep H G SchollEugene P van PuijenbroekHarald E VonkemanSander W TasMichael T NurmohamedBart J F van den BemtNaomi T JessurunPublished in: Expert opinion on drug safety (2022)
There were no differences in frequencies and nature of patient-reported ADRs attributed to adalimumab and etanercept between different IRDs. However, more research is needed to align patients' and health-care professionals' perspectives to improve knowledge on disease-specific ADRs.
Keyphrases
- patient reported
- healthcare
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- juvenile idiopathic arthritis
- chronic kidney disease
- oxidative stress
- peritoneal dialysis
- ankylosing spondylitis
- clinical trial
- patient reported outcomes
- disease activity
- systemic lupus erythematosus
- double blind
- health information